Corrigendum to “2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk” (Atherosclerosis (2019) 290 (140–205), (S0021915019314595), (10.1016/j.atherosclerosis.2019.08.014))

Task Force Members; ESC National Cardiac Societies; ESC Committee for Practice Guidelines (CPG)

doi:10.1016/j.atherosclerosis.2019.12.004

Corrigendum to “2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk” (Atherosclerosis (2019) 290 (140–205), (S0021915019314595), (10.1016/j.atherosclerosis.2019.08.014))

Task Force Members
, ESC National Cardiac Societies
, ESC Committee for Practice Guidelines (CPG)

Research output: Contribution to journal › Comment/debate/note

11 Citations (Scopus)

Abstract

In row 4 of Table 3, ‘should’ should read as ‘may’; In 4.2.1, paragraph 3, ‘should’ should read ‘may’ to read ‘Overall, CAC score assessment with CT may be considered in individuals … ’ Also in the second row of ‘Recommendations for cardiovascular imaging for risk assessment of atherosclerotic cardiovascular disease,’ the Class should read ‘llb’; In the second paragraph of 7.5.2, ‘5–10 mg of monacolin K’ should read ‘2.5–10 mg’; and in the Key messages section, number 4, ‘ApoB may be a better measure of an individual's exposure to atherosclerotic lipoproteins' should read ‘ApoB may be a better measure of an individual's exposure to pro atherogenic lipoproteins'.

Original language	English
Pages (from-to)	80-82
Number of pages	3
Journal	Atherosclerosis
Volume	294
DOIs	https://doi.org/10.1016/j.atherosclerosis.2019.12.004
Publication status	Published - Feb 2020
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1016/j.atherosclerosis.2019.12.004

Fingerprint

Dive into the research topics of 'Corrigendum to “2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk” (Atherosclerosis (2019) 290 (140–205), (S0021915019314595), (10.1016/j.atherosclerosis.2019.08.014))'. Together they form a unique fingerprint.

Cite this

Task Force Members, ESC National Cardiac Societies, & ESC Committee for Practice Guidelines (CPG) (2020). Corrigendum to “2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk” (Atherosclerosis (2019) 290 (140–205), (S0021915019314595), (10.1016/j.atherosclerosis.2019.08.014)). Atherosclerosis, 294, 80-82. https://doi.org/10.1016/j.atherosclerosis.2019.12.004

Task Force Members ; ESC National Cardiac Societies ; ESC Committee for Practice Guidelines (CPG). / Corrigendum to “2019 ESC/EAS Guidelines for the management of dyslipidaemias : lipid modification to reduce cardiovascular risk” (Atherosclerosis (2019) 290 (140–205), (S0021915019314595), (10.1016/j.atherosclerosis.2019.08.014)). In: Atherosclerosis. 2020 ; Vol. 294. pp. 80-82.

@article{3cb11c16c8ec4730bb2377d995807459,

title = "Corrigendum to “2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk” (Atherosclerosis (2019) 290 (140–205), (S0021915019314595), (10.1016/j.atherosclerosis.2019.08.014))",

abstract = "In row 4 of Table 3, {\textquoteleft}should{\textquoteright} should read as {\textquoteleft}may{\textquoteright}; In 4.2.1, paragraph 3, {\textquoteleft}should{\textquoteright} should read {\textquoteleft}may{\textquoteright} to read {\textquoteleft}Overall, CAC score assessment with CT may be considered in individuals … {\textquoteright} Also in the second row of {\textquoteleft}Recommendations for cardiovascular imaging for risk assessment of atherosclerotic cardiovascular disease,{\textquoteright} the Class should read {\textquoteleft}llb{\textquoteright}; In the second paragraph of 7.5.2, {\textquoteleft}5–10 mg of monacolin K{\textquoteright} should read {\textquoteleft}2.5–10 mg{\textquoteright}; and in the Key messages section, number 4, {\textquoteleft}ApoB may be a better measure of an individual's exposure to atherosclerotic lipoproteins' should read {\textquoteleft}ApoB may be a better measure of an individual's exposure to pro atherogenic lipoproteins'.",

author = "\{Task Force Members\} and \{ESC National Cardiac Societies\} and \{ESC Committee for Practice Guidelines (CPG)\} and Francois Mach and Colin Baigent and Catapano, \{Alberico L.\} and Koskinas, \{Konstantinos C.\} and Manuela Casula and Lina Badimon and Chapman, \{M. John\} and \{De Backer\}, \{Guy G.\} and Victoria Delgado and Ference, \{Brian A.\} and Graham, \{Ian M.\} and Alison Halliday and Ulf Landmesser and Borislava Mihaylova and Pedersen, \{Terje R.\} and Gabriele Riccardi and Richter, \{Dimitrios J.\} and Sabatine, \{Marc S.\} and Taskinen, \{Marja Riitta\} and Lale Tokgozoglu and Olov Wiklund and Djamaleddine Nibouche and Zelveian, \{Parounak H.\} and Peter Siostrzonek and Ruslan Najafov and \{van de Borne\}, Philippe and Belma Pojskic and Arman Postadzhiyan and Lambros Kypris and Jind{\v r}ich {\v S}pinar and Larsen, \{Mogens Lytken\} and Eldin, \{Hesham Salah\} and Margus Viigimaa and Strandberg, \{Timo E.\} and Jean Ferrieres and Rusudan Agladze and Ulrich Laufs and Loukianos Rallidis and Laszlo Bajnok and Thorbjorn Gudjonsson and Vincent Maher and Yaakov Henkin and Gulizia, \{Michele Massimo\} and Aisulu Mussagaliyeva and Gani Bajraktari and Alina Kerimkulova and Gustavs Latkovskis and Omar Hamoui and Rimvydas Slapikas and Laurent Visser",

note = "Publisher Copyright: {\textcopyright} 2019 [The Author/The Authors]",

year = "2020",

month = feb,

doi = "10.1016/j.atherosclerosis.2019.12.004",

language = "English",

volume = "294",

pages = "80--82",

journal = "Atherosclerosis",

issn = "0021-9150",

publisher = "Elsevier Ireland Ltd",

}

Task Force Members, ESC National Cardiac Societies & ESC Committee for Practice Guidelines (CPG) 2020, 'Corrigendum to “2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk” (Atherosclerosis (2019) 290 (140–205), (S0021915019314595), (10.1016/j.atherosclerosis.2019.08.014))', Atherosclerosis, vol. 294, pp. 80-82. https://doi.org/10.1016/j.atherosclerosis.2019.12.004

Corrigendum to “2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk” (Atherosclerosis (2019) 290 (140–205), (S0021915019314595), (10.1016/j.atherosclerosis.2019.08.014)). / Task Force Members; ESC National Cardiac Societies; ESC Committee for Practice Guidelines (CPG).
In: Atherosclerosis, Vol. 294, 02.2020, p. 80-82.

Research output: Contribution to journal › Comment/debate/note

TY - JOUR

T1 - Corrigendum to “2019 ESC/EAS Guidelines for the management of dyslipidaemias

T2 - lipid modification to reduce cardiovascular risk” (Atherosclerosis (2019) 290 (140–205), (S0021915019314595), (10.1016/j.atherosclerosis.2019.08.014))

AU - Task Force Members

AU - ESC National Cardiac Societies

AU - ESC Committee for Practice Guidelines (CPG)

AU - Mach, Francois

AU - Baigent, Colin

AU - Catapano, Alberico L.

AU - Koskinas, Konstantinos C.

AU - Casula, Manuela

AU - Badimon, Lina

AU - Chapman, M. John

AU - De Backer, Guy G.

AU - Delgado, Victoria

AU - Ference, Brian A.

AU - Graham, Ian M.

AU - Halliday, Alison

AU - Landmesser, Ulf

AU - Mihaylova, Borislava

AU - Pedersen, Terje R.

AU - Riccardi, Gabriele

AU - Richter, Dimitrios J.

AU - Sabatine, Marc S.

AU - Taskinen, Marja Riitta

AU - Tokgozoglu, Lale

AU - Wiklund, Olov

AU - Nibouche, Djamaleddine

AU - Zelveian, Parounak H.

AU - Siostrzonek, Peter

AU - Najafov, Ruslan

AU - van de Borne, Philippe

AU - Pojskic, Belma

AU - Postadzhiyan, Arman

AU - Kypris, Lambros

AU - Špinar, Jindřich

AU - Larsen, Mogens Lytken

AU - Eldin, Hesham Salah

AU - Viigimaa, Margus

AU - Strandberg, Timo E.

AU - Ferrieres, Jean

AU - Agladze, Rusudan

AU - Laufs, Ulrich

AU - Rallidis, Loukianos

AU - Bajnok, Laszlo

AU - Gudjonsson, Thorbjorn

AU - Maher, Vincent

AU - Henkin, Yaakov

AU - Gulizia, Michele Massimo

AU - Mussagaliyeva, Aisulu

AU - Bajraktari, Gani

AU - Kerimkulova, Alina

AU - Latkovskis, Gustavs

AU - Hamoui, Omar

AU - Slapikas, Rimvydas

AU - Visser, Laurent

PY - 2020/2

Y1 - 2020/2

N2 - In row 4 of Table 3, ‘should’ should read as ‘may’; In 4.2.1, paragraph 3, ‘should’ should read ‘may’ to read ‘Overall, CAC score assessment with CT may be considered in individuals … ’ Also in the second row of ‘Recommendations for cardiovascular imaging for risk assessment of atherosclerotic cardiovascular disease,’ the Class should read ‘llb’; In the second paragraph of 7.5.2, ‘5–10 mg of monacolin K’ should read ‘2.5–10 mg’; and in the Key messages section, number 4, ‘ApoB may be a better measure of an individual's exposure to atherosclerotic lipoproteins' should read ‘ApoB may be a better measure of an individual's exposure to pro atherogenic lipoproteins'.

AB - In row 4 of Table 3, ‘should’ should read as ‘may’; In 4.2.1, paragraph 3, ‘should’ should read ‘may’ to read ‘Overall, CAC score assessment with CT may be considered in individuals … ’ Also in the second row of ‘Recommendations for cardiovascular imaging for risk assessment of atherosclerotic cardiovascular disease,’ the Class should read ‘llb’; In the second paragraph of 7.5.2, ‘5–10 mg of monacolin K’ should read ‘2.5–10 mg’; and in the Key messages section, number 4, ‘ApoB may be a better measure of an individual's exposure to atherosclerotic lipoproteins' should read ‘ApoB may be a better measure of an individual's exposure to pro atherogenic lipoproteins'.

UR - https://www.scopus.com/pages/publications/85076858833

U2 - 10.1016/j.atherosclerosis.2019.12.004

DO - 10.1016/j.atherosclerosis.2019.12.004

M3 - Comment/debate/note

C2 - 31870624

AN - SCOPUS:85076858833

SN - 0021-9150

VL - 294

SP - 80

EP - 82

JO - Atherosclerosis

JF - Atherosclerosis

ER -

Task Force Members, ESC National Cardiac Societies, ESC Committee for Practice Guidelines (CPG). Corrigendum to “2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk” (Atherosclerosis (2019) 290 (140–205), (S0021915019314595), (10.1016/j.atherosclerosis.2019.08.014)). Atherosclerosis. 2020 Feb;294:80-82. doi: 10.1016/j.atherosclerosis.2019.12.004

Corrigendum to “2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk” (Atherosclerosis (2019) 290 (140–205), (S0021915019314595), (10.1016/j.atherosclerosis.2019.08.014))

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this